

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Immunoblot images were collected using ImageQuant LAS 4000 (Version 1.3). qRT-PCR data were collected using ABS 7300 System SDS Software (Version 1.4.0.27). Protein lysate concentration data were collected using Microplate Manager Macintosh OS X (MPMIII Version 1.0d1). Cell-Titer Glo luminescence data were collected using BMG Labtech Optima (Version 2.20R2).

Data analysis

Data were analyzed using R Studio (Version 1.1.456), R (3.5.1), and Prism 7. Sanger sequencing data were analyzed using SnapGene Viewer (4.2.11).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

We include a data availability statement in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No sample size calculation was performed—growth assays were plated at five technical replicates per sample and RT-PCR assays at three technical replicates per sample to capture relevant technical variation.
Data exclusions	Individual qRT-PCR or CellTiter-Glo wells were excluded from analyses if they differed dramatically from the other two or four technical replicates.
Replication	All growth assays were repeated with at least two or three biological replicates (see Figures 2 and 3, Supplementary Figures 2 and 4). All attempts at validation were successful.
Randomization	Not relevant to this study—samples for cellular assays were plated from the same culture on the same day at the same time.
Blinding	Investigators were not blinded—needed to maintain cell line and sgRNA labels for tracking and analysis of data.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

### Methods

n/a	Involved in the study	n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies	<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines	<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology	<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms		
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants		
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data		

## Antibodies

Antibodies used	EXOSC8—Proteintech #11979-1-AP, Lot #00014147 PRIM1—Cell Signaling Technology #4725, Ref: 07/2016, Lot #1 Vinculin—Sigma #V9131, Clone hVIN-1; Batch #036M4797V, #118M4777V, #018M4779V
Validation	EXOSC8: validated in 4 immunoblots on manufacturer's website and two publications (Pubmed IDs: 24989451, 23844004); signal decreases dramatically in lines with targeted EXOSC8 inactivation by two different sgRNAs. PRIM1: validated in 1 immunoblot on manufacturer's website; signal decreases dramatically in lines with targeted PRIM1 inactivation by two different sgRNAs. Vinculin: validated in 1 immunoblot on manufacturer's website and numerous publications.

## Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	Cell lines were originally purchased from ATCC or the Broad Institute of MIT and Harvard.
Authentication	Cell lines were genotyped for the SNP of interest using Sanger and/or next-generation sequencing.
Mycoplasma contamination	Cell lines were not tested for mycoplasma contamination.
Commonly misidentified lines (See <a href="#">ICLAC</a> register)	No commonly misidentified cell lines were included in this study.